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Black AfricaAbstract Aim of the work: To determine the epidemiological, clinical, paraclinical and therapeutic
proﬁle of bone metastases of prostate cancer.
Patients and methods: This was the study of a series of cases of bonemetastases of prostate cancer.
Results: Fifty-eight of 2881 patients (2%) admitted to the Rheumatology department during
21 years suffered from a bone metastasis of prostate cancer. The average age at admission was
64.27 ± 8.9 years while the disease duration was 28.43 ± 44.16 months. Prostate cancer was known
in 27% of cases before the metastasis and the metastasis was revealing in 73% of cases. The average
time between the diagnosis of prostate cancer and the development ofmetastasis was 5.4 ± 3.67 years
in 27% of the cases. The main manifestations of patients with bone metastases were alteration of gen-
eral condition (81.03%), inﬂammatory bone pain (75.86%), voiding disorders (58.62%) and spinal
cord compression (36.20%). The spine was the main area of pain (89.65%). An osteosclerosis was
the most observed radiological lesion (63.79%). The prostate speciﬁc antigen average was
301.87 ± 738.23 ng/ml. Histopathological examination was performed in 18 patients and conﬁrmed
adenocarcinoma of the prostate. Hormone therapy, mainly by anti-androgens (86.20%), surgical
treatment (32.75%) and orthopedic treatment (29.31%) was administered in our patients. A severe
anemia caused the death of seven patients (12.06%) during hospitalization.
Conclusion: Diagnosis of cancer of the prostate is late and takes place in themajority of cases at the
stage of metastasis.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis.Open access under CC BY-NC-ND license.1. Introduction
Prostate cancer is by far the most common cancer in men and
the second leading cause of cancer death after lung cancer in
developed countries [1,2]. Prostate metastases are a common
reason for hospitalization in rheumatology. They occur after
36 K. Kakpovi et al.the diagnosis of prostate cancer although they may be reveal-
ing. Among the patients with prostate cancer, approximately
70% have a proven clinical metastatic bone at the time of
death [3]. In Africa in general, the diagnosis is not always easy
and care remains poor due to lack of both technical, ﬁnancial,
and above all the still very limited access to appropriate health
care facilities. Prostate cancer ranks ﬁrst among bone metasta-
sis osteophilic cancers [4,5]. The purpose of this study was to
determine the epidemiological, clinical, paraclinical, and ther-
apeutic proﬁle of bone metastases of prostate cancer in a rheu-
matological service in Lome´.Table 1 Distribution of the 58 patients according to the
circumstances of discovery of bone metastasis of prostate
cancer.
Number
(58 cases)
Percentage
Alteration of the general condition 47 81.03
Inﬂammatory bone pain 44 75.86
Mixed bone pain* 14 24.14
Voiding disorders 34 58.62
Spinal cord compression 21 36.20
Systematic search for visceral metastasis 16 27.58
Externalized bleeding (hematuria: 4 cases,
bleeding per rectum: 3 cases)
07 12.06
* Pain with some features of inﬂammatory pain and mechanical
pain.2. Patients and methods
This study was retrospectively performed on a series of cases
admitted in the Department of Rheumatology, University
Hospital Sylvanus Olympio, Lome´, Togo’s capital between
January 1990 and December 2010. The series included all pa-
tients diagnosed with bone metastasis of prostate cancer. Most
of these patients were diagnosed with the cancer after being
admitted in the Rheumatology ward for inﬂammatory bone
pain. The study was approved by the ethics committee and
all patients gave an informed consent for a study. The demo-
graphic, clinical, paraclinical and therapeutic data of patients
were collected from their records. The diagnosis of bone
metastasis was based essentially on the clinical picture (inﬂam-
matory bone pain and alteration of the general condition) and
radiological features (mainly osteosclerosis). The prostatic ori-
gin of metastasis was based essentially on the clinical picture
(voiding disorders, history of prostate cancer, enlarged and
indurated prostate) and serum prostate speciﬁc antigen
(PSA) concentration >100 ng/ml. For economic reasons, a
ﬁnger guided biopsy of the prostate was conducted for histo-
logical conﬁrmation only when the diagnosis was uncertain
(bone lysis, PSA less than 100 ng/ml). Gleason histopatholo-
gical grading system has been used for classiﬁcation of
prostatic carcinomas [6]. The grading of prostate adenocarci-
noma indicates the histological differentiation of the
carcinoma and rises with the severity of the prognosis: from
2 to 6: well differentiated tumor, 7: moderately differentiated
tumor and from 8 to 10 undifferentiated tumor [6].
The anemia corresponded to a hemoglobin concentration
lower than 10 g/dl. A plasma creatinine greater than 12 mg/l
was considered renal insufﬁciency. Serum calcium greater than
110 mg/l was considered hypercalcemia. Erythrocyte sedimen-
tation rate greater than 20 mm in the ﬁrst hour was considered
accelerated. The combination of fatigue, anorexia, weight loss
and pallor or the presence of at least three of these symptoms
was considered impaired general condition. A weight loss
greater than 10% was considered massive and a weight loss be-
low 10% was considered moderate. A serum PSA level inferior
to 4 ng/ml was considered normal. Analgesics were always
administered in progressive stages from Tier 1 to Tier 3 (Tier
1: paracetamol, nonsteroidal antiinﬂammatory drugs; Tier 2:
codeine or tramadol; Tier 3: morphine), depending on the
intensity of the pain [7]. The pain intensity was measured on
a 100 mm visual analog scale for pain (VAS). VAS inferior
to 40 mm: moderate pain (Tier 1), from 40 to 70 mm: intense
pain (Tier 2), and from 80 to 100 mm: very intense pain (Tier
3). The reduction of pain by 70% was considered as positive
effect of ﬂutamide therapy. No patient received bone scan ormagnetic resonance imaging (MRI) due to the absence of scin-
tigraphy and MRI in Togo at the time of the study.
3. Results
Of the 2881 rheumatic patients admitted in 21 years, 58 (2%)
had bone metastases of prostate cancer. Their average age at
admission was 64.27 ± 8.90 years with extremes of 45 and
82 years and the age group most affected was between 65
and 74 years (23 cases, i.e., 39.65%). The mean disease dura-
tion was 28.43 ± 44.16 months and the median was
20 months. The mean duration of hospitalization was
38.10 ± 48.20 days and the median was 27 days. Prostate can-
cer was seen in 16 patients (27%) before metastasis and it was
revealing in the remaining 42 (73%). The average time between
the diagnosis of prostate cancer and the development of metas-
tasis was 5.4 ± 3.67 years in 27% of the cases. The onset of the
disease was insidious in 46 patients (79%) and in 12 others
sudden (21%). Alteration of the general condition (47 cases;
81.03%) inﬂammatory bone pain (44 cases, 75.86%), voiding
disorders (34 cases, 58.62%) and spinal cord compression (21
cases; 36.20%) were the main manifestations in our patients
(Table 1). The alteration of the general condition was reﬂected
mainly by a massive weight loss in 28 cases (48.27%) and a
moderate weight loss in the remaining 19 patients (32.7%).
The average body mass index was 21.9 ± 4.48 kg/m2, with a
range from 14.69 to 31.14 kg/m2. Only 15% of our patients
had a BMI greater than 25 kg/m2. Voiding disorders were rep-
resented by urinary frequency, dysuria and dribbling at the end
of voiding, respectively in 46.55%, 25.86% and 13.79% of
cases. All patients suffered from bone pain and the spine was
the main site of pain (52 cases, 89.65%) with a clear preference
for the lumbar segment (47 cases, 81.03%). The other sites of
spinal pain were thoracic segment (4 cases, 6.89%) and cervical
segment (1 case, 1.72%). Most other affected sites were the
long bones (10 cases, 17.24%), the pelvis (9 cases, 15.51%)
and the ribs (7 cases, 12.06%). An affection of more than
one region was revealed in 15.51% cases. Digital rectal exam-
ination revealed an abnormality of the prostate in 47 patients.
The prostate was enlarged in 42 patients, indurated in 30 pa-
tients and irregular in 13 patients. Anemia was found in 28 pa-
tients and was microcytic and aplastic with an average
hemoglobin level of 7.6 g/dl. Erythrocyte sedimentation rate
Table 2 Distribution of the 58 patients according to the result
of the X-ray of the painful bone segment.
Number (58 cases) Percentage
Osteosclerosis 37 63.79
Bone lysis 15 25.86
Vertebral compression 13 22.41
Diﬀuse bone demineralization 09 15.51
Pathological fracture 04 06.89
Figure 1 Osteosclerosis of the spine.
Figure 2 Lysis of the fourth cervical vertebra (C4).
Figure 3 Osteosclerosis of the pelvis and the femur.
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86.4 ± 36.74 mm in the ﬁrst hour with a range from 10 mm
to 147 mm. The prostate speciﬁc antigen average was
301.87 ± 738.23 ng/ml with a range from 35 ng/ml to
5000 ng/ml and the median was 105 ng/ml. Eighteen patients
(31.03%) had PSA levels <100 ng/ml. Creatinine was high
in four patients with a range from 21 mg/l to 45 mg/l. Hyper-
calcemia was observed in four (6.89%) of the 34 patients with
a range from 121 mg/l to 135 mg/l. Osteosclerosis (37 cases,
63.79%), bone lysis (15 cases, 25.86%) and vertebral compres-
sion (13 cases, 22.41%) were the main radiographic lesions ob-
served (Table 2). The locations were mostly the spine (30 cases,
51.72%) (Figs. 1 and 2), followed by the pelvis (17 cases,
29.31%) (Fig3) and the femur (3 cases, 5.17%). Histopatholo-
gical examination was performed in 18 patients and showed a
grading of the prostate adenocarcinoma higher than or equal
to six in all these patients. All the 58 patients received a palli-
ative treatment consisting of analgesics (58 cases), corticoste-
roids (9 cases), bisphosphonates (4 cases), and blood
transfusion (23 cases) as needed. Analgesics were always
administered in progressive stages from Tier 1 to Tier 3,
depending on the intensity of the pain. Eight patients were inTier 1, 40 in Tier 2 and 10 in Tier 3. Morphine was the last re-
sort in Tier 3 patients. Hormonal treatment was administered
in 50 patients (86.20%), while only 19 patients (32.75%) had
beneﬁted from surgical treatment and 17 patients (29.31%)
from orthopedic treatment. Of the 50 patients who received
hormone therapy, 41 received ﬂutamide at a dose of 750 mg
per day, three received cyproterone acetate at a dose of
300 mg per day, two received tetrasodium fosfestrol at a dose
of 900 mg per day, two others received triptorelin at a dose of
11.25 mg every three months, one patient received leuprorelin
at a dose of 3.75 mg every month, and one patient received
diethylstilbestrol at a dose of 3 mg per day. Of the 41 patients
who received ﬂutamide, the effect was positive in 35 patients
after 15 days, on an average with a range from 3 days to
31 days and zero in the other six after 21 days. After a mean
follow up duration of 36 ± 13.35 months with a range from
14 months to 48 months, three patients had side effects in the
form of gynecomastia, sexual impotence and diarrhea. Four
patients experienced a loss of effectiveness of the ﬂutamide
therapy after 18–24 months. Of the 9 patients who received
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tive in four patients after 15 days, and one patient developed
gynecomastia. Surgical treatment was performed in 10 patients
before the onset of metastasis and in nine others after the onset
of metastasis. It consisted mainly of a testicular pulpectomy
(12 patients) and a total prostatectomy (7 patients). Of the
17 patients who received orthopedic treatment, it consisted
mainly of spinal orthoses. A severe anemia caused the death
of seven patients (12.06%) during hospitalization.
4. Discussion
Metastasis was the ﬁrst presentation in 42 of the 58 patients
who had bone metastases from prostate cancer. The strict
interpretation of the results requires taking into account selec-
tion biases and the narrowness of the technical platform. This
was a hospital-based study that took into account only
patients admitted at the hospital and viewed in the rheumatol-
ogy department, which constitutes a bias making it impossible
to generalize our results. The mean duration of symptoms
prior to presentation was 28 months in our study,
10.3 ± 17.1 months in Nigeria [8]. Because the serum prostatic
speciﬁc antigen (PSA) is routinely performed from the age of
50 years since the late 1980’s in France, prostate cancer can
be diagnosed before symptom onset [4].The average disease
duration in our study reﬂects on the one hand the limited
and late recourse to specialized agencies and on the other hand
the lack of medical information of the population without
ignoring the impact of unfavorable socio-economic conditions.
However, the shortcomings of our study do not alter its epide-
miological signiﬁcance. We noted over a period of 21 years, 58
cases (2%) of bone metastases of prostate cancer. These results
are similar to those found in other African studies [9,10]. In the
study of Houzou et al. [9], 26/13,517 patients admitted to the
rheumatology department in 15 years had bone metastases of
prostate cancer and 6/509 patients in the two years study of
Daboiko et al. [10]. In the present study, the average age at
admission of patients was 64.27 years and the age ranging
from 65 to 74 years was the most represented. Many African
series [11–13], Asian [14,15], European [16–18] and American
[19,20] have found similar results (Table 3). In our study, early
signs of cancer were seen in 27% of cases and bone metastasis
was revealing prostate cancer in 73% of cases. The same obser-Table 3 Average age at presentation of patients with prostate
cancer in our series and in others series.
Authors Origin of
the publication
Age at presentation
in years
Our series Africa 64.27 (45–82)*
Ammani et al. [11] Africa 71 (53–90)
Eke et al. [12] Africa 71.6 (45–88)
Gueye et al. [13] Africa 69 (52–88)
Cooperberg et al. [14] Asia 66.2 ± 8.7**
Peyromaure et al. [15] Asia 72 (49–92)
Botto et al. [16] Europe 71.22 ± 8.25
Vandecandelaere et al. [17] Europe 63 (38–85)
Mohile et al. [20] America 71 (51–81)
* Mean age (range).
** Mean age ±SD.vation was made in other African series [11–13]. The alteration
of the general condition, inﬂammatory bone pain, voiding dis-
orders and spinal cord compression were the main manifesta-
tions, respectively in 81.03%, 75.86%, 58.62%, and 36.20% of
the cases. Botto et al. [16] and Rigaud et al. [21] in France
found 47.50% and 30% of their patients, respectively to have
impaired general condition. Such a difference is probably due
to the consistent delay in consultation of patients observed in
our African populations [11,21,8]. Botto et al. [16] found 69%
and 70% of their patients to have bone pain and voiding dis-
orders, respectively.
Osteosclerosis was the main radiographic ﬁnding in 63.79%
of cases. This result is consistent with those of Ammani et al.
[11] and Vandelcandelaere et al. [17]. Prostate speciﬁc antigen
(PSA) level increases with the extension of the disease. PSA lev-
els <50 ng/ml indicate usually that the tumor is conﬁned to the
prostate. PSA between 50 and 100 ng/ml indicated metastases
of cancer prostate in 80% of cases and PSA more than
100 ng/ml indicated bone metastases of cancer prostate [22]. In-
deed, Western [23], Asian series [24], and ours found a median
PSA greater than 100 ng/ml in patients with metastatic prostate
cancer. None of our patients performed a routine PSA. The fre-
quency of mass screening (performing routine PSA and/or
biopsy in elderly subjects) is however higher in developed coun-
tries [16,23–25]. In our study, treatment had consisted of surgi-
cal castration in 32.75% and medical one in 86.20% cases.
Hormonal treatment is imposed against surgical castration
[26]. In Western studies, the implementation of surgical castra-
tion has become limited [15,27]. In our series, at most one sur-
gical castration was made per year. This frequency is very
limited due to the fact that most of our patients were diagnosed
at the stage of metastasis and that they prefer to keep for a little
time their manliness despite the high cost of the hormonal ther-
apy which is at least ﬁve times the minimumwage guaranteed in
Togo. On the contrary, the frequency of surgical castration is
high in studies from Nigeria [28], Taiwan [24], and especially
in China [15] due to the cost of chemical castration. Lachand
et al. [29] also noted by order of frequency hormonal therapy
in 91.54% of cases and surgical castration in 47.88% of cases.
In the present study, seven patients (12.06%) died during hos-
pitalization due to the late diagnosis and especially the anemic
complications. Alteration of the general condition, bone pain,
Gleason score of 8 to 10, and visceral metastasis remained as
independent risk factors predicting a reduced cancer speciﬁc
survival in other series [21,24]. In conclusion, diagnosis of can-
cer of the prostate is late and takes place in the majority of cases
at the stage of metastasis.
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